APA (7th ed.) Citation

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., . . . Agarwal, N. (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: Final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The lancet, 406(10502), . https://doi.org/10.1016/S0140-6736(25)00683-X

Chicago Style (17th ed.) Citation

Fizazi, Karim, et al. "Talazoparib Plus Enzalutamide in Men with HRR-deficient Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet 406, no. 10502 (2025). https://doi.org/10.1016/S0140-6736(25)00683-X.

MLA (9th ed.) Citation

Fizazi, Karim, et al. "Talazoparib Plus Enzalutamide in Men with HRR-deficient Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Results from the Randomised, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet, vol. 406, no. 10502, 2025, https://doi.org/10.1016/S0140-6736(25)00683-X.